Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie M Vose

Showing results (141-150 of 299) with videos related to

Pageof 30
Sort By:
British Journal of Haematology|February 28, 2009
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphomaThomas M Habermann, Izidore S Lossos, Glen Justice, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 18, 2015
Central Nervous System Complications and Outcomes After Allogeneic Hematopoietic Stem Cell TransplantationVijaya Raj Bhatt, Vamshi Balasetti, Jagar A Jasem, et al.
British Journal of Haematology|May 4, 2021
A novel MYC-non-IG fusion in refractory diffuse large B-cell lymphomaCheng Wang, Pamela A Althof, Chengfeng Bi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 14, 2009
Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomesKoen van Besien, Jeanette Carreras, Philip J Bierman, et al.
Transfusion|May 26, 2012
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphomaJonathan L Kaufman, Christopher R Flowers, Karen D Rados, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2015
A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory LymphomaAndrew M Evens, Sriram Balasubramanian, Julie M Vose, et al.
Blood|November 9, 2002
A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survivalChristine P Hans, Dennis D Weisenburger, Julie M Vose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphomaJia Ruan, Peter Martin, Richard R Furman, et al.
Blood|February 26, 2005
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomabJohn M Bennett, Mark S Kaminski, John P Leonard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2022
Where Are All the Women in Industry Advisory Boards?Rachna T Shroff, Karyn A Goodman, Janice M Mehnert, et al.
Pageof 30

Showing results (141-150 of 299) with videos related to

Sort By:
Pageof 30
British Journal of Haematology|February 28, 2009
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphomaThomas M Habermann, Izidore S Lossos, Glen Justice, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 18, 2015
Central Nervous System Complications and Outcomes After Allogeneic Hematopoietic Stem Cell TransplantationVijaya Raj Bhatt, Vamshi Balasetti, Jagar A Jasem, et al.
British Journal of Haematology|May 4, 2021
A novel MYC-non-IG fusion in refractory diffuse large B-cell lymphomaCheng Wang, Pamela A Althof, Chengfeng Bi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 14, 2009
Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomesKoen van Besien, Jeanette Carreras, Philip J Bierman, et al.
Transfusion|May 26, 2012
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphomaJonathan L Kaufman, Christopher R Flowers, Karen D Rados, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2015
A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory LymphomaAndrew M Evens, Sriram Balasubramanian, Julie M Vose, et al.
Blood|November 9, 2002
A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survivalChristine P Hans, Dennis D Weisenburger, Julie M Vose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphomaJia Ruan, Peter Martin, Richard R Furman, et al.
Blood|February 26, 2005
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomabJohn M Bennett, Mark S Kaminski, John P Leonard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2022
Where Are All the Women in Industry Advisory Boards?Rachna T Shroff, Karyn A Goodman, Janice M Mehnert, et al.
Pageof 30